Intech Investment Management LLC Buys Shares of 18,565 DexCom, Inc. (NASDAQ:DXCM)

Intech Investment Management LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 18,565 shares of the medical device company’s stock, valued at approximately $2,575,000.

Other large investors have also recently bought and sold shares of the company. Capital World Investors grew its stake in shares of DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Norges Bank acquired a new position in shares of DexCom in the 4th quarter worth approximately $540,178,000. Artisan Partners Limited Partnership grew its stake in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Capital Research Global Investors grew its stake in shares of DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of DexCom in the 4th quarter worth approximately $231,773,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent analyst reports. Morgan Stanley decreased their target price on shares of DexCom from $132.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Canaccord Genuity Group raised their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, Raymond James raised their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $139.33.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $0.96 during trading on Friday, reaching $111.66. The stock had a trading volume of 2,274,469 shares, compared to its average volume of 2,634,305. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The firm has a market capitalization of $44.40 billion, a price-to-earnings ratio of 72.04, a P/E/G ratio of 2.73 and a beta of 1.16. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The stock has a fifty day simple moving average of $118.01 and a two-hundred day simple moving average of $124.61.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. As a group, analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,112 shares of company stock valued at $480,861. 0.30% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.